TY - JOUR
T1 - Characterization of gait variability in multiple system atrophy and Parkinson’s disease
AU - Sidoroff, Victoria
AU - Raccagni, Cecilia
AU - Kaindlstorfer, Christine
AU - Eschlboeck, Sabine
AU - Fanciulli, Alessandra
AU - Granata, Roberta
AU - Eskofier, Björn
AU - Seppi, Klaus
AU - Poewe, Werner
AU - Willeit, Johann
AU - Kiechl, Stefan
AU - Mahlknecht, Philipp
AU - Stockner, Heike
AU - Marini, Kathrin
AU - Schorr, Oliver
AU - Rungger, Gregorio
AU - Klucken, Jochen
AU - Wenning, Gregor
AU - Gaßner, Heiko
N1 - Funding Information:
We thank our patients and families and the MSA Coalition for supporting this research. This work was supported by the Bavarian Ministry for Economy, Regional Development and Energy via the Medical Valley Award 2017 (FallRiskPD Project) and EIT Health. BE, JK, and HG are supported by Mobilise-D from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 820820. Furthermore, we are grateful for the support of VASCage (Research centre on vascular ageing and stroke, Innsbruck, Austria) for supporting the recruitment of our control group.
Funding Information:
Victoria Sidoroff: none. Cecilia Raccagni: none. Christine Kaindlstorfer: none. Sabine Eschlboeck: none. Alessandra Fanciulli: none concerning this project. A.F. reports royalties from springer Nature, speaker fees and honoraria from the Ordensklinikum Linz, Austrian Parkinson Society, International Parkinson Disease and Movement Disorder Society and Theravance Biopharma and research grant from Stitching Parkinson Fond and the Österreichischer Austauschdienst outside of the submitted work. Roberta Granata: none. Björn Eskofier: none concerning this project. B.E. is supported by Mobilise-D from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 820820. He further received an institutional research grant from the Bavarian Ministry of Economic Affairs and Media, Energy and Technology, Germany (Medical Valley Award, FallRiskPD). Klaus Seppi: none concerning this project. K.S. reports personal fees from Teva, UCB, Lundbeck, AOP Orphan Pharmaceuticals AG, Roche, Grünenthal and Abbvie, honoraria from the International Parkinson and Movement Disorders Society, research grants from FWF Austrian Science Fund, Michael J. Fox Foundation, and International Parkinson and Movement Disorder Society, outside the submitted work. Werner Poewe: none concerning this project. W.P. reports personal fees from AbbVie, Affiris, AstraZeneca, BIAL, Britannia, Intec, Ipsen, Lundbeck, Neuroderm, Denali Pharmaceuticals, Novartis, Orion Pharma, Roche, Teva, UCB and Zambon (consultancy and lecture fees in relation to clinical drug development programmes for PD). Johann Willeit: none. Stefan Kiechl: none concerning this project. S.K. is CSO of VASCage, a COMET Research Centre of the Austria Research Promotion Agency. Philipp Mahlknecht: none. Heike Stockner: none. Kathrin Marini: K. M. was supported by a research grant from the Tiroler Wirtschaftsförderung (grant number UNI-0404/2245). Oliver Schorr: none. Gregorio Rungger: none. Jochen Klucken: none concerning this project. J.K. is supported by Mobilise-D from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 820820. He further received an institutional research grant from the Bavarian Ministry of Economic Affairs and Media, Energy and Technology, Germany (Medical Valley Award, FallRiskPD) and reports institutional research grants from EIT-Health; EIT-Digital; EU (H2020), German Research Foundation (DFG). Industry sponsored institutional IITs and grants from Alpha-Telemed AG. Compensation and honoraria from serving on scientific advisory boards and lecturing from Ever Neuro Pharma GmbH, TEVA Pharma GmbH, Bial Deutschland GmbH; Celgene GmbH, and Magisan GmbH. Gregor K. Wenning: none concerning this project. G.W. reports personal fees from Biohaven, Theravance, UCB, Lundbeck, and Ono, honoraria from the Austrian Autonomic Society, research grants from FWF Austrian Science Fund, International Parkinson and Movement Disorder Society, and US MSA Coalition, outside of the submitted work. Heiko Gaßner: none concerning this project. H.G. is supported by Mobilise-D from the Innovative Medicines Initiative 2 Joint Undertaking under grant Agreement No. 820820. He further received an institutional research grant from the Bavarian Ministry of Economic Affairs and Media, Energy and Technology, Germany (Medical Valley Award, FallRiskPD). HG received an institutional research grant by the Federal Ministry of Education and Research (project: treatHSP) and Huntington-Stiftung of the Deutsche Huntington Hilfe e.V. HG received further support by the Medical Research Foundation at the University Hospital Erlangen and the Förderverein für HSP-Forschung e.V. outside of the submitted work.
Funding Information:
We thank our patients and families and the MSA Coalition for supporting this research. This work was supported by the Bavarian Ministry for Economy, Regional Development and Energy via the Medical Valley Award 2017 (FallRiskPD Project) and EIT Health. BE, JK, and HG are supported by Mobilise-D from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 820820. Furthermore, we are grateful for the support of VASCage (Research centre on vascular ageing and stroke, Innsbruck, Austria) for supporting the recruitment of our control group.
Funding Information:
Open access funding provided by University of Innsbruck and Medical University of Innsbruck. This was an academic and not an industry supported study. This work was performed at the Department of Neurology, Innsbruck Medical University, Innsbruck, Austria and the Bruneck hospital in Bruneck, Italy. Assessment of the control group was supported by a research grant from the Tiroler Wirtschaftsförderung [Grant Number UNI-0404/2245].
Publisher Copyright:
© 2020, The Author(s).
PY - 2021/5
Y1 - 2021/5
N2 - Background: Gait impairment is a pivotal feature of parkinsonian syndromes and increased gait variability is associated with postural instability and a higher risk of falls. Objectives: We compared gait variability at different walking velocities between and within groups of patients with Parkinson-variant multiple system atrophy, idiopathic Parkinson’s disease, and a control group of older adults. Methods: Gait metrics were recorded in 11 multiple system atrophy, 12 Parkinson’s disease patients, and 18 controls using sensor-based gait analysis. Gait variability was analyzed for stride, swing and stance time, stride length and gait velocity. Values were compared between and within the groups at self-paced comfortable, fast and slow walking speed. Results: Multiple system atrophy patients displayed higher gait variability except for stride time at all velocities compared with controls, while Parkinson’s patients did not. Compared with Parkinson’s disease, multiple system atrophy patients displayed higher variability of swing time, stride length and gait velocity at comfortable speed and at slow speed for swing and stance time, stride length and gait velocity (all P < 0.05). Stride time variability was significantly higher in slow compared to comfortable walking in patients with multiple system atrophy (P = 0.014). Variability parameters significantly correlated with the postural instability/gait difficulty subscore in both disease groups. Conversely, significant correlations between variability parameters and MDS-UPDRS III score was observed only for multiple system atrophy patients. Conclusion: This analysis suggests that gait variability parameters reflect the major axial impairment and postural instability displayed by multiple system atrophy patients compared with Parkinson’s disease patients and controls.
AB - Background: Gait impairment is a pivotal feature of parkinsonian syndromes and increased gait variability is associated with postural instability and a higher risk of falls. Objectives: We compared gait variability at different walking velocities between and within groups of patients with Parkinson-variant multiple system atrophy, idiopathic Parkinson’s disease, and a control group of older adults. Methods: Gait metrics were recorded in 11 multiple system atrophy, 12 Parkinson’s disease patients, and 18 controls using sensor-based gait analysis. Gait variability was analyzed for stride, swing and stance time, stride length and gait velocity. Values were compared between and within the groups at self-paced comfortable, fast and slow walking speed. Results: Multiple system atrophy patients displayed higher gait variability except for stride time at all velocities compared with controls, while Parkinson’s patients did not. Compared with Parkinson’s disease, multiple system atrophy patients displayed higher variability of swing time, stride length and gait velocity at comfortable speed and at slow speed for swing and stance time, stride length and gait velocity (all P < 0.05). Stride time variability was significantly higher in slow compared to comfortable walking in patients with multiple system atrophy (P = 0.014). Variability parameters significantly correlated with the postural instability/gait difficulty subscore in both disease groups. Conversely, significant correlations between variability parameters and MDS-UPDRS III score was observed only for multiple system atrophy patients. Conclusion: This analysis suggests that gait variability parameters reflect the major axial impairment and postural instability displayed by multiple system atrophy patients compared with Parkinson’s disease patients and controls.
KW - Gait analysis
KW - Gait variability
KW - Multiple system atrophy
KW - Parkinson’s disease
KW - Wearable sensors
UR - http://www.scopus.com/inward/record.url?scp=85098479112&partnerID=8YFLogxK
U2 - 10.1007/s00415-020-10355-y
DO - 10.1007/s00415-020-10355-y
M3 - Article
C2 - 33382439
AN - SCOPUS:85098479112
SN - 0340-5354
VL - 268
SP - 1770
EP - 1779
JO - Journal of Neurology
JF - Journal of Neurology
IS - 5
ER -